1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Iran Pharmaceuticals and Healthcare Report Q4 2015

Iran Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 120 pages

Includes 3 FREE quarterly updates

BMI View: Iran's pharmaceutical market holds significant potential for innovative drugmakers,particularly with the easing of sanctions. This potential is unlikely to be realised in the near term, however,as the government operates in favour of the well developed domestic industry.

Headline Expenditure Projections

- Pharmaceuticals: IRR60.70tn (USD2.35bn) in 2014 to IRR69.55trn (USD1.93bn) in 2015; +14.6% inlocal currency terms and -17.8% in US dollar terms. Forecast upgraded slightly from previous quarter.

- Healthcare: IRR695.67trn (USD21.88bn) in 2014 to IRR792.81trn (USD22.02bn) in 2015; +14.0% inlocal currency terms and +0.7% in US dollar terms. Forecast in line with previous quarter.

Table Of Contents

Iran Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 13
Operational Risk 14
Industry Forecast 16
Pharmaceutical Market Forecast 16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019) 19
Healthcare Market Forecast 20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 24
Prescription Drug Market Forecast 25
Patented Drug Market Forecast 26
Generic Drug Market Forecast 27
OTC Market Forecast 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019) 32
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 34
Economy To Grow Again On Sanctions Relief 34
Table: Economic Activity (Iran 2010-2019) 40
Table: GDP By Expenditure (Iran 2012-2019) 40
Industry Risk Reward Indices 42
Middle East and Africa Risk/Reward Index 42
Iran Risk/Reward Index 49
Rewards 49
Risks 49
Market Overview 51
Industry Trends And Developments 52
Epidemiology 52
Table: HIV/AIDS Prevalence In Iran 54
Healthcare Sector 54
Table: Healthcare Resources (Iran 2009-2014) 57
Table: Healthcare Personnel (Iran 2009-2014) 58
Table: Healthcare Activity (Iran 2009-2014) 58
Healthcare Insurance 58
International Healthcare Collaboration 60
Traditional Herbal Remedies 60
Research and Development 61
Biotechnology 62
Clinical Trials 65
Regulatory Development 66
Intellectual Property Regime 68
Counterfeit Medicines 69
Pricing And Reimbursement 70
Competitive Landscape 72
Pharmaceutical Sector 72
Generic Drugmakers 74
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009 74
Pharmaceutical Distribution 77
Table: Leading Distributors, Iranian Year To March 20 2008 79
Pharmaceutical Retail Sector 79
Company Profile 80
Amin Pharmaceutical Company 80
Caspian Tamin Pharmaceutical Company 82
Darou Pakhsh 85
Exir Pharmaceuticals 88
GlaxoSmithKline 90
Merck and Co 92
Novartis 94
Pars Darou 96
Pfizer 98
Pharmieco 100
Sanofi 102
Sina Darou Pharmaceutical Company 104
Zahravi Pharmaceutical Company 106
Demographic Forecast 109
Table: Population Headline Indicators (Iran 1990-2025) 110
Table: Key Population Ratios (Iran 1990-2025) 110
Table: Urban/Rural Population And Life Expectancy (Iran 1990-2025) 111
Table: Population By Age Group (Iran 1990-2025) 111
Table: Population By Age Group % (Iran 1990-2025) 112
Glossary 114
Methodology 116
Pharmaceutical Expenditure Forecast Model 116
Healthcare Expenditure Forecast Model 116
Notes On Methodology 117
Risk/Reward Index Methodology 118
Index Overview 119
Table: Pharmaceutical Risk/Reward Index Indicators 119
Indicator Weightings 120

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.